The Secondary Hyperoxaluria Drug Market is witnessing an unprecedented surge in clinical interest and financial valuation. Unlike primary hyperoxaluria, which is a rare genetic defect, secondary hyperoxaluria is an acquired condition often resulting from underlying gastrointestinal disorde